Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of MabionCD20 versus MabThera in rheumatoid arthritis
2012-003194-25Phase 3Completed
- Sponsor
- Mabion S.A.
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MabionCD20 in rheumatoid arthritis (RA) (2 arms), sponsored by Mabion S.A. Primary endpoint: ACR20 response at Week 24. Started Sep 2012; status: completed.
02
Drugs
MabionCD20
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003194-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003194-25.